Podrobný výpis o publikaci

MÁJEK, Ondřej, Ahti ANTTILA, Marc ARBYN, Evert Ben VAN VEEN, Birgit ENGESAETER a Stefan LONNBERG. The legal framework for European cervical cancer screening programmes. European journal of public health. OXFORD: OXFORD UNIV PRESS, 2019, roč. 29, č. 2, s. 345-350. ISSN 1101-1262. Dostupné z: https://dx.doi.org/10.1093/eurpub/cky200.

Další formáty: BibTeX LaTeX RIS

TY  - JOUR
ID  - 1531401
AU  - Májek, Ondřej - Anttila, Ahti - Arbyn, Marc - van Veen, Evert Ben - Engesaeter, Birgit - Lonnberg, Stefan
PY  - 2019
TI  - The legal framework for European cervical cancer screening programmes
JF  - European journal of public health
VL  - 29
IS  - 2
SP  - 345-350
EP  - 345-350
PB  - OXFORD UNIV PRESS
SN  - 11011262
KW  - European cervical cancer screening programmes
UR  - http://dx.doi.org/10.1093/eurpub/cky200
L2  - http://dx.doi.org/10.1093/eurpub/cky200
N2  - Background: A comprehensive legal framework needs to be developed to run the health services and to regulate the information systems required to manage and to ensure the quality of cancer screening programmes. The aim of our study was to document and to compare the status of legal basis for cervical screening registration in European countries. Methods: An electronic questionnaire including questions on governance, decision-making structures and legal framework was developed. The primary responses were collected by September 2016. Results: We sent the questionnaire to representatives of 35 European countries (28 countries of the EU, with the United Kingdom included as 4 countries; 4 EFTA member countries: Iceland, Liechtenstein, Norway, and Switzerland); responses were collected from 33 countries. The legal framework makes it possible to personally invite individuals in 29 countries (88%). Systematic screening registration in an electronic registry is legally enshrined in 23 countries (70%). Individual linkage of records between screening and cancer registries is allowed in 19 of those countries. Linkage studies involving cancer and screening registries have been conducted in 15 countries. Conclusion: Although the majority of EU/EFTA countries have implemented population-based screening, only half of them have successfully performed record linkage studies, which are nevertheless a key recommendation for quality assurance of the entire screening process. The European legislation is open to the possibility of using health data for these purposes; however, member states themselves must recognize the public interest to create a legal basis, which would enable all the necessary functions for high-quality cancer screening programmes.
ER  -

Základní údaje
Originální název	The legal framework for European cervical cancer screening programmes
Autoři	MÁJEK, Ondřej (203 Česká republika, garant, domácí), Ahti ANTTILA (246 Finsko), Marc ARBYN (56 Belgie), Evert Ben VAN VEEN (528 Nizozemské království), Birgit ENGESAETER (578 Norsko) a Stefan LONNBERG (246 Finsko).
Vydání	European journal of public health, OXFORD, OXFORD UNIV PRESS, 2019, 1101-1262.

Další údaje
Originální jazyk	angličtina
Typ výsledku	Článek v odborném periodiku
Obor	10103 Statistics and probability
Stát vydavatele	Velká Británie a Severní Irsko
Utajení	není předmětem státního či obchodního tajemství
WWW	URL
Impakt faktor	Impact factor: 2.391
Kód RIV	RIV/00216224:14110/19:00109669
Organizační jednotka	Lékařská fakulta
Doi	http://dx.doi.org/10.1093/eurpub/cky200
UT WoS	000463809200027
Klíčová slova anglicky	European cervical cancer screening programmes
Štítky	14119612, rivok
Příznaky	Mezinárodní význam, Recenzováno
Změnil	Změnila: Soňa Böhmová, učo 232884. Změněno: 16. 5. 2019 14:33.

Anotace
Background: A comprehensive legal framework needs to be developed to run the health services and to regulate the information systems required to manage and to ensure the quality of cancer screening programmes. The aim of our study was to document and to compare the status of legal basis for cervical screening registration in European countries. Methods: An electronic questionnaire including questions on governance, decision-making structures and legal framework was developed. The primary responses were collected by September 2016. Results: We sent the questionnaire to representatives of 35 European countries (28 countries of the EU, with the United Kingdom included as 4 countries; 4 EFTA member countries: Iceland, Liechtenstein, Norway, and Switzerland); responses were collected from 33 countries. The legal framework makes it possible to personally invite individuals in 29 countries (88%). Systematic screening registration in an electronic registry is legally enshrined in 23 countries (70%). Individual linkage of records between screening and cancer registries is allowed in 19 of those countries. Linkage studies involving cancer and screening registries have been conducted in 15 countries. Conclusion: Although the majority of EU/EFTA countries have implemented population-based screening, only half of them have successfully performed record linkage studies, which are nevertheless a key recommendation for quality assurance of the entire screening process. The European legislation is open to the possibility of using health data for these purposes; however, member states themselves must recognize the public interest to create a legal basis, which would enable all the necessary functions for high-quality cancer screening programmes.

Anotace

Background: A comprehensive legal framework needs to be developed to run the health services and to regulate the information systems required to manage and to ensure the quality of cancer screening programmes. The aim of our study was to document and to compare the status of legal basis for cervical screening registration in European countries. Methods: An electronic questionnaire including questions on governance, decision-making structures and legal framework was developed. The primary responses were collected by September 2016. Results: We sent the questionnaire to representatives of 35 European countries (28 countries of the EU, with the United Kingdom included as 4 countries; 4 EFTA member countries: Iceland, Liechtenstein, Norway, and Switzerland); responses were collected from 33 countries. The legal framework makes it possible to personally invite individuals in 29 countries (88%). Systematic screening registration in an electronic registry is legally enshrined in 23 countries (70%). Individual linkage of records between screening and cancer registries is allowed in 19 of those countries. Linkage studies involving cancer and screening registries have been conducted in 15 countries. Conclusion: Although the majority of EU/EFTA countries have implemented population-based screening, only half of them have successfully performed record linkage studies, which are nevertheless a key recommendation for quality assurance of the entire screening process. The European legislation is open to the possibility of using health data for these purposes; however, member states themselves must recognize the public interest to create a legal basis, which would enable all the necessary functions for high-quality cancer screening programmes.